Table S1. Description of KRAS mutational status. Abbreviations: *N*, number of cases; wt, wild type.

	Entire sample	**G12C**	**G12A**	**G12D**	**G12R**	**G12S**	**G12V**	**G13D**	**wt**
N (%)	44 (100%)	11 (25%)	1 (2%)	5 (11%)	1 (2%)	1 (2%)	5 (11%)	1 (2%)	19

Table S2. Description of AIC Optimised Cox Proportional Hazard Models for G12C+/-. Abbreviations: CI, confidence interval; G12C+, patients with G12C mutation in *KRAS* gene; *p*, *p* value.

Risk Factor	**Model 1**			**Model 2**		
	Hazard Ratio	**95% CI**	***p***	**Hazard Ratio**	**95% CI**	***p***
G12C+	0.39	0.16-0.96	0.04	0.24	0.09-0.66	0.01
Likelihood ratio test	$\chi2(1)=5.07$		0.02	$\chi2(1)=10.18$		<0.01
Wald Test	$\chi2(1)=4.24$		0.04	$\chi2(1)=7.82$		0.01
Log Rank Test	$\chi2(1)=4.53$		0.03	$\chi2(1)=8.88$		<0.01
Concordance	0.58			0.62		

Table S3. Description of AIC Optimised Cox Proportional Hazard Models for *KRAS*+/-. Abbreviations: CI, confidence interval; *KRAS*+, patients with any mutation in *KRAS* gene; *p*, *p* value.

Risk Factor	**Model 1**			**Model 2**		
	Hazard Ratio	**95% CI**	***p***	**Hazard Ratio**	**95% CI**	***p***
KRAS+	0.63	0.32-1.24	0.18	0.47	0.23-0.97	0.04
Presence of brain metastases				1.55	0.90-2.69	0.11
Likelihood ratio test	$\chi2(1)=1.75$		0.2	$\chi2(2)=5.4$		0.07
Wald Test	$\chi2(1)=1.79$		0.2	$\chi2(2)=5.2$		0.06
Log Rank Test	$\chi2(1)=1.82$		0.2	$\chi2(2)=5.72$		0.06
Concordance	0.57			0.62		